A single 25mg dose of psilocybin reduced depression symptoms significantly within 48 hours, with effects lasting over three months. That’s the headline finding from a new randomised, double-blind clinical trial out of Karolinska Institutet in Sweden, published in JAMA Network Open yesterday.
But he 12-month picture is more complex than the short-term data, and suggests repeated dosing may be necessary. Let’s break down what actually happened.
The Setup
Thirty-five people with moderate to severe recurrent major depression took part. They were randomly split into two groups: one received a single oral dose of 25mg psilocybin; the other received 100mg niacin (vitamin B3), chosen as an active placebo because it produces a noticeable physical flush that mimics the sense of “something happening.”
Both groups received five sessions of psychotherapeutic support spread across 17 days, including one preparation session, one dosing session, and three integration sessions. On dosing day, participants lay down with eye masks, listened to music, and were monitored for seven hours.
Depression was measured using the MADRS (Montgomery–Åsberg Depression Rating Scale), a standard clinical tool, rated by doctors who didn’t know which treatment participants had received. Measurements were taken at days 8, 15, 42, and 365.
What the Data Showed
The results at day 8 were statistically significant and, in clinical terms, meaningful. MADRS scores dropped an average of 9.7 points in the psilocybin group, compared to 2.4 points in the placebo group. That’s a group difference of 7.3 points in favour of psilocybin.
But the more striking finding came from the self-reported data. Participants in the psilocybin group were already reporting meaningful symptom reduction by day two. Two days after a single dose.
For context, standard SSRIs typically take two to six weeks to produce meaningful effects. Psilocybin’s onset here is comparable only to ketamine, and possibly faster than electroconvulsive therapy.
By the six-week mark, 53% of the psilocybin group were in full remission, compared to just 6% of the placebo group. The quality of life and functional disability measures told the same story. Psilocybin participants were doing meaningfully better across the board.
Those effects held through day 42 on the clinician-rated scale, and through day 102 on participants’ self-reports.
Where It Gets More Complicated
At one year, the difference between the two groups had disappeared.The psilocybin participants had not relapsed catastrophically, but many of those who’d received the placebo had also improved over time – as tends to happen with episodic depression.
The 12-month remission rate for the psilocybin group was 53%. For the niacin group, it had climbed to 41%. That gap isn’t considered statistically significant.
This is important and underappreciated. Previous psilocybin studies have sometimes pointed to long-term effects without a control group to compare against. Depression, left alone, often improves. When you include a placebo arm over a full year, that natural recovery trajectory becomes visible, and the picture gets more nuanced.
The researchers’ own interpretation is that repeated doses, or some form of maintenance protocol, are probably needed to sustain the gains. A single treatment may be a powerful reset, but it doesn’t appear to be a permanent fix.
The Safety Picture
The treatment was generally well-tolerated. Most side effects were mild or moderate and resolved quickly. Things like headache, anxiety, hallucinations, and agitation, which are expected during and shortly after a strong psychedelic experience.
Two caveats worth noting. First, two participants in the psilocybin group experienced severe and persistent anxiety that required medical attention weeks after dosing. This isn’t unique to this study, but it’s important. Psilocybin is not a benign substance for everyone, and the context, support, and screening around its use matter enormously.
Second, and unsurprisingly, the blinding failed.
The Blinding Problem
By day 365, 94% of psilocybin participants had correctly guessed they’d received the real thing. The the doctors scoring depression severity also correctly identified treatment allocation at rates well above chance.
This is a fundamental methodological challenge for the entire field. A truly double-blind trial is one where neither the participant nor the assessor knows what was given. But psilocybin produces a powerful, distinctive subjective experience. Niacin, even with its flush, is clearly not the same thing. Blinding is extremely difficult to maintain.
Why does this matter? Because expectation influences outcome. If you believe you’ve received the “real” treatment, you may unconsciously report better, feel genuinely better through the psychological mechanism of expectancy, and interact differently with your therapists. This doesn’t mean psilocybin doesn’t work, but it does mean the effect sizes may be somewhat inflated by expectancy effects. By how much? We don’t know yet.
The Karolinska team is candid about this: “We want to understand how factors such as treatment expectations and lack of blinding affect the results, as previous studies may have exaggerated the treatment effects.”
What’s Coming Next
The researchers collected PET scans, blood samples, and cerebrospinal fluid from participants before and after dosing. Those results haven’t been published yet, but they’ll be looking directly at whether psilocybin changes synaptic density in the brain.
This connects to one of the most compelling mechanistic hypotheses in the field: that psilocybin promotes synaptogenesis, the growth of new synaptic connections, potentially reversing some of the structural neural changes associated with chronic depression. It’s been demonstrated in preclinical (animal) studies. Whether it shows up in living human brains is the next frontier.
The Summary
This is a small but rigorous study. Thirty-five people isn’t a large sample, and the researchers are cautious about drawing sweeping conclusions from secondary and long-term outcomes. What it does add, with unusually high methodological credibility:
- Psilocybin produces rapid antidepressant effects in standard (non-treatment-resistant) depression – a population that most previous trials ignored.
- The effects are clinically meaningful and statistically significant out to 6 weeks.
- Self-reported improvement begins as early as day 2.
- The 12-month picture is more complex than the short-term data, and suggests repeated dosing may be necessary.
- Blinding integrity remains a major unsolved problem for the entire field of psychedelic research.
- For most people, it’s well-tolerated. For some, it’s not.
Psilocybin is not going to replace every depression treatment. But this study adds to a growing body of evidence that it is a unique medicine. One that acts fast, works differently from anything currently on the market, and deserves serious, rigorous investigation.
Which is exactly what’s happening.
Want this kind of breakdown every week?
The Spore Report covers the science of psychedelics, fungi, and neuroscience. Join thousands of readers who want to actually understand what the research says. Subscribe to The Spore Report newsletter here.
